QLGN Stock Price | Qualigen Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Qualigen Therapeutics Inc • QLGN

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Qualigen Therapeutics Inc

Ticker

QLGN

Trading on

NASDAQ

ISIN

US74754R1032

Industry

Biotechnology

Sector

Healthcare

CEO

Kevin A. Richardson II

Headquarters

5857 Owens Avenue, Carlsbad, CA, United States, 92008

Employees

Website

https://qlgntx.com

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of treatments for adult and pediatric cancer in the United States. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase 1 clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS, for the treatment of advanced solid tumors, which is in a preclinical stage. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.

Metrics

BasicAdvanced

Market cap

$3.6M

P/E ratio

EPS

-$1.48

Dividend Yield

0.00%

Beta

0.03

Forward P/E ratio

EBIDTA

$-6.9M

Ex dividend date

Price & volume

Market cap

$3.6M

Average daily volume

2.5M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

0.39

Price to book

0.41

Earnings

EPS

-$1.48

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-6.9M

Revenues (TTM)

$5M

Revenues per share (TTM)

$1.03

Technicals

Beta

0.03

52-week High

$11.50

52-week Low

$2.00

50-day moving average

$3.46

200-day moving average

$3.94

Short ratio

1.29

Short %

1.53%

Management effectiveness

ROE (TTM)

-841.66%

ROA (TTM)

-211.25%

Profit margin

0.00%

Gross profit margin

$0.3M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

13.70%

Share stats

Outstanding Shares

1.6M

Float

1.6M

Insiders %

1.70%

Institutions %

0.09%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$5.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$1,045.22

Q2 • 15Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-0.9M

-∞%

Q1 • 25

$-2.6M

0.00%

Q2 • 25

NaN%

209.20%

0.00%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$4.7M

$2M

42.84%

Q1 • 25

$2.8M

98.84%

Q2 • 25

-39.24%

40.20%

130.74%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-2.3M

$-0.3M

$4.1M

$-2.3M

Q1 • 25

$-1.6M

$0.8M

$-1.6M

Q2 • 25

-29.97%

-81.54%

-29.97%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Qualigen Therapeutics Inc share?

Qualigen Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Qualigen Therapeutics Inc have?

Qualigen Therapeutics Inc currently has 1.6M shares.

Does Qualigen Therapeutics Inc pay dividends?

No, Qualigen Therapeutics Inc doesn't pay dividends.

What is Qualigen Therapeutics Inc 52 week high?

Qualigen Therapeutics Inc 52 week high is $11.50.

What is Qualigen Therapeutics Inc 52 week low?

Qualigen Therapeutics Inc 52 week low is $2.00.

What is the 200-day moving average of Qualigen Therapeutics Inc?

Qualigen Therapeutics Inc 200-day moving average is $3.94.

Who is Qualigen Therapeutics Inc CEO?

The CEO of Qualigen Therapeutics Inc is Kevin A. Richardson II.

How many employees Qualigen Therapeutics Inc has?

Qualigen Therapeutics Inc has 0 employees.

What is the market cap of Qualigen Therapeutics Inc?

The market cap of Qualigen Therapeutics Inc is $3.6M.

What is the P/E of Qualigen Therapeutics Inc?

The current P/E of Qualigen Therapeutics Inc is null.

What is the EPS of Qualigen Therapeutics Inc?

The EPS of Qualigen Therapeutics Inc is -$1.48.

What is the PEG Ratio of Qualigen Therapeutics Inc?

The PEG Ratio of Qualigen Therapeutics Inc is null.

What do analysts say about Qualigen Therapeutics Inc?

According to the analysts Qualigen Therapeutics Inc is considered a buy.